Enterome

The SIDNEY study evaluates EO2463 for treating indolent non-Hodgkin lymphoma, assessing safety, tolerability, and efficacy in monotherapy and combination therapy.

OncoMimics are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, respectively.

Download the article about Enterome in MedNous. (pdf format)

2023 SNO Annual Meeting

2024 AACR Annual Meeting

Enterome and Scancell have reached positive Phase 2 milestones with a new generation of active immunotherapies to treat melanoma and blood cancers, respectively. Their highly differentiated approaches offer insights and strategies for harnessing the immune system more effectively.

Enterome appointed Prof. Alessandra Cervino as Head of Discovery in 2014.

Enterome raised 10 million euros in Series B funding in 2014.

SEVENTURE PARTNERS launched a new 120 million euro innovation fund, Health for Life Capital.

Enterome develops next-generation products for immune diseases, including cancer, based on microbiome research.

Christelle has over 20 years of experience in senior finance roles, including 10 years in the pharmaceutical industry at Fournier/Solvay Pharma. She previously worked at Laboratoire Hepatoum-Dermophil Indien as General Secretary and led finance departments at Almavia and Polygon/Munters France-Belgium.

David Klatzmann, MD, PhD, is a renowned immunologist who contributed to the discovery of HIV, identifying its cytopathic effects. He is a professor at Sorbonne University and holds roles at Pierre and Marie Curie Medical School and Pitié-Salpêtrière Hospital, including Chief of Biotherapy and Coordinator of the Clinical Investigation Center.

Justin Eyquem, PhD, is an Assistant Professor at the University of California, San Francisco, and an investigator at the Gladstone-UCSF Institute for Genomic Immunology. He co-founded Mnemo Therapeutics and studies engineering T lymphocytes for cancer treatment. He earned his PhD from the University of Paris-Diderot.

Marie-Laure co-founded Enterome and has led corporate operations since then.

Enterome develops immunomodulatory drugs for cancer using OncoMimics peptides. Its Mimicry platform decodes gut microbiome-immune system interactions to identify novel treatments.

The human gut microbiome contains millions of bacterial proteins that interact with the human host. Some resemble human hormones, cytokines, and tumor antigens, triggering responses beyond the gut.

Enterome is a clinical-stage biopharmaceutical company developing drugs by decoding gut microbiome interactions.

Enterome prioritizes user privacy and complies with data protection laws in France.